What were the key takeaways from Brainsway's earnings call?

What is Brainsway's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Brainsway year over year?

What is the market's earnings forecast for Brainsway next quarter?

What factors drove the changes in Brainsway's revenue and profit?

Did Brainsway beat or miss consensus estimates last quarter?

What does Brainsway do and what are its main business segments?

What is Brainsway's gross profit margin?

- **Revenue Growth**: Q4 2025 revenue up 27% YoY to $14.5 million, with full-year $52.2 million (27% YoY). RPO at $70 million (43% YoY growth).
- **FDA Expansion**: Deep TMS cleared for adolescents (15-21) with MDD, targeting 5 million U.S. adolescents.
- **SWIFT Protocol**: 70% reduction in clinic visits, with payer coverage from Premera and Highmark.
- **Strategic Investments**: 5 mental health network investments, 200+ pipeline partners, and $11 million convertible loan with Neurolief for Proliv RX.
- **2026 Guidance**: Revenue $66-68 million (27-30% YoY), adjusted EBITDA $12-14 million (86-100% YoY growth).

**【CEO Summary】**
- Q4 2025 revenue reached $14.5 million, up 27% YoY, with full-year revenue of $52.2 million (27% YoY growth). 95 Deep TMS systems shipped, bringing total installed base to 1,700 units.
- Remaining Performance Obligations (RPO) rose to $70 million (43% YoY), driven by long-term leasing contracts with enterprise customers.
- FDA cleared Deep TMS for adolescents (15-21) with MDD, expanding addressable patient population to 5 million U.S. adolescents.
- SWIFT protocol reduces clinic visits by 70%, with payers like Premera and Highmark covering accelerated treatment.
- Invested in 5 mental health networks, with 200+ potential new partners, supporting rapid scaling and patient access.
- Strategic partnership with Neurolief for Proliv RX, the first FDA-approved wearable neuromodulation device for treatment-resistant MDD.

**【CFO Financial Commentary】**
- Q4 2025 gross profit: $11.1 million (76% margin), up from $8.5 million (75% margin) in Q4 2024.
- Full-year 2025 adjusted EBITDA: $7 million (13% of revenue), up from $4.5 million (11% of revenue) in 2024.
- Cash position: $68 million, with no debt, supporting growth and strategic investments.
- 2026 guidance: Revenue $66-68 million (27-30% YoY growth), adjusted EBITDA $12-14 million (86-100% YoY growth).

**【Q&A Highlights】**
- Over 50% of Q4 units leased, reflecting strong recurring revenue model.
- Alcohol Use Disorder (AUD) trial recruiting 200+ patients across 10 U.S. centers, with feasibility studies for neurology (Alzheimer's/dementia) in 3 centers.
- Pricing: No ASP decreases anticipated; premium pricing supported by unique value proposition.
- SWIFT protocol adoption accelerating with ketamine/psychedelic therapy combinations, driven by reduced treatment duration and improved patient retention.

BrainsWay Ltd. (BWAY) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 $13.5M (+29% YoY), full-year guidance raised to $51-52M. 
- **Accelerated Protocol**: 6-day MDD treatment protocol driving demand. 
- **Strategic Investments**: $20M equity in mental health providers and Neurolief (up to $11M convertible loan). 
- **Financial Strength**: 75% gross margin, $70.7M cash, updated guidance for 6-7% operating profit. 
- **Global Expansion**: APAC and Europe key growth markets.

**【CEO Summary Section】**
- **Record Q3 Revenue**: $13.5 million, up 29% YoY, driven by 90 Deep TMS systems shipped (43% YoY increase). Full-year guidance raised to $51-52 million (from $50-52 million). 
- **Accelerated Protocol Adoption**: FDA-approved 6-day MDD treatment protocol (vs. 4-week traditional), with early demand signals. 
- **Minority Investments**: $20 million strategic equity investment in mental health providers (e.g., Stella Mental Health, Axis) and Neurolief (up to $11 million convertible loan). 
- **Lease Model Dominance**: 70% of sales via multi-year leases, with $65 million remaining performance obligations. 

**【CFO Financial Commentary】**
- **Gross Profit**: $10.2 million (75% margin), stable vs. prior year. 
- **Operating Expenses**: $4.7M (Sales/Marketing), $2.4M (R&D), $1.8M (G&A), driven by strategic initiatives. 
- **Cash Flow**: $70.7 million ending cash, positive operating cash flow. 
- **Guidance Update**: Operating profit 6-7% of revenue (vs. 4-5%), EBITDA 13-14% (vs. 12-13%). 

**【Q&A Highlights】**
- **Accelerated Protocol**: CEO expects adoption to boost patient convenience and demand. 
- **Minority Investments**: Pipeline for 2026 includes high-growth, profitable enterprises. 
- **Neurolief Update**: FDA clearance anticipated by end-2025, targeting VA, IDNs, and TMS clinics. 
- **International Growth**: Focus on APAC (Japan, China, India) and Europe (Germany, France).

BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

- **Revenue Record**: Q2 2025 revenue of $12.6 million (+26% YoY) driven by 88 Deep TMS systems shipped.
- **Recurring Revenue Dominance**: 70% of engagements via multiyear leases, with $62 million backlog.
- **FDA Milestone**: Accelerated TMS protocol submission; FDA response expected by Q4 2025.
- **Strategic Growth**: $5 million invested in Stella MSO; targeting 5-10 similar deals by end-2026.
- **Financial Strength**: $78.3 million cash, updated 2025 guidance of $50-52 million revenue.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q2 2025 revenue reached $12.6 million, a 26% year-over-year increase, driven by 88 Deep TMS systems shipped (35% YoY growth) and a total installed base of 1,522 systems.
- **Recurring Revenue Model**: 70% of customer engagements are multiyear lease agreements, with a backlog of $62 million in remaining performance obligations.
- **Strategic Focus**: Three pillars include expanding market awareness, advancing R&D (e.g., accelerated TMS protocol submitted to FDA), and global expansion. The FDA is expected to respond by Q4 2025 on the accelerated protocol, which reduces treatment duration from 6 weeks to 6 days.
- **Strategic Investments**: $5 million invested in Stella MSO, with plans for 5-10 similar minority investments by end-2026, targeting mental health networks.

**【CFO Financial Commentary】**
- **Financial Highlights**: Gross profit of $9.5 million (75% margin), operating profit of $600,000, and net profit of $2 million. Cash reserves stand at $78.3 million, up $30.2 million YoY.
- **Expense Growth**: Sales & marketing (+30%), R&D (+35%), and G&A (+14%) reflect investments in commercial expansion, clinical trials, and strategic initiatives.
- **Guidance Update**: Full-year 2025 revenue guidance raised to $50-52 million (22-27% growth), with operating profit targeting 4-5% of revenue and EBITDA 12-13%.

**【Q&A Key Highlights】**
- **Accelerated Protocol Commercialization**: FDA response expected by Q4 2025; potential to increase patient accessibility and utilization.
- **Sales Team Expansion**: 26 FTEs (16 sales, 10 practice development) supporting U.S. and international growth.
- **OCD Placements**: 30 OCD systems shipped in Q2, aligning with expanding clinical indications.
- **Strategic Investment Success**: Stella MSO partnership achieved a 50% increase in TMS utilization, showcasing the value of technology + training collaborations.

BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 27% YoY to $11.5M, driven by 81 systems shipped (42% YoY)
- **Clinical Leadership**: 60%+ OCD response rate, 1st FDA-cleared TMS for OCD & PTSD reimbursement expansion
- **Financial Health**: 75% gross margin, $72M cash, 20-24% 2025 revenue growth guidance
- **Pipeline Progress**: Accelerated MDD protocol FDA clearance expected Q4 2025, psychedelic-TMS trial Q3 launch

**【CEO Key Highlights】**
- Q1 2025 Revenue: $11.5M (27% YoY growth), Systems Shipped: 81 units (42% YoY), Backlog: ~$60M
- **Market Expansion**: 80% of new sales from greenfield customers, 20% from competitive conversions
- **Clinical Momentum**: 
  - OCD Response Rate: 60%+ (1st FDA-cleared TMS for OCD)
  - PTSD Reimbursement Expansion in Israel
  - Accelerated MDD Protocol Submission to FDA expected Q4 2025
- **Revenue Models**: Pay-per-use in Israel, multi-year agreements with large networks
- **Gross Margin**: Consistent 75% despite geopolitical trade policy monitoring

**【CFO Financial Breakdown】**
- Q1 2025 Financials:
  - Revenue: $11.5M (27% YoY)
  - Gross Profit: $8.6M (75% margin)
  - Operating Expenses: $7.9M (Sales: $4.2M, R&D: $2.3M, G&A: $1.5M)
  - Net Income: $1.1M (vs $0.1M YoY)
  - Cash Position: $72M
- **Full Year 2025 Guidance**: 
  - Revenue: $49-51M (20-24% YoY growth)
  - Operating Margin: 3-4%
  - Adjusted EBITDA: 11-12%

**【Q&A Key Takeaways】**
1. **Clinical Trials**: 
   - Accelerated MDD Protocol FDA Clearance expected Q4 2025
   - PTSD & Adolescent MDD Data Submissions Q4 2025
   - Psychedelics + TMS Combination Trial Launch Q3 2025
2. **Product Adoption**: 
   - 57 OCD Coils Shipped Q1, Total Installed Base: ~850
   - TMS 360 System: Mix of upgrades & new installations for addiction/dementia
3. **Financial Strategy**: 
   - No immediate stock buyback plans; prioritizing R&D & growth
   - No material impact from trade policies on 2025 gross margin

BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript

- **Revenue Acceleration**: Q4 2024 up 27% YoY to $11.4M; full year $41M (29% growth). 2025 guidance: $49-51M (20-24% growth). 
- **Enterprise Dominance**: 75 systems shipped (25% YoY), enterprise accounts driving repeat orders. 
- **Clinical Breakthroughs**: First TMS for OCD, elderly MDD, and AUD pilot success. 
- **Pipeline Momentum**: TMS 360 AUD trial Q3 2025; accelerated MDD data Q3 2025. 
- **Financial Strength**: $69.4M cash, 75% gross margin, 6+ quarters of EBITDA positivity. 
- **Strategic Focus**: Organic growth via R&D, partnerships, and psychedelic clinic expansion.

**【CEO Key Highlights】**
- **Revenue Growth**: Q4 2024 revenue of $11.4M (27% YoY), full year $41M (29% YoY). 2025 guidance: $49-51M (20-24% growth). 
- **Enterprise Sales Momentum**: 75 systems shipped in Q4 (25% YoY), book-to-bill ratio >1.0. Large enterprise accounts driving repeat orders. 
- **Clinical Expansion**: 
  - OCD treatment (first TMS approved for resistant OCD) with 60%+ response rates. 
  - Elderly MDD (FDA expanded age limit to 86). 
  - AUD pilot study showing efficacy with accelerated protocol. 
- **Pipeline Progress**: 
  - TMS 360 multi-center trial for AUD in H2 2025. 
  - Accelerated MDD protocol data expected Q3 2025. 
  - Feasibility studies for Alzheimer's/Parkinson's with TMS 360. 
- **Financial Strength**: $69.4M cash as of Dec 2024, no debt. 75% gross margin maintained. 

**【CFO Financial Summary】**
- **Topline**: Q4 2024: $11.4M (27% YoY). Full year: $41M (29% YoY). 
- **Gross Margin**: 75% Q4 and full year. 
- **Profitability**: 
  - Q4 net income $1.5M (vs $0.1M YoY). 
  - 6 consecutive quarters of positive EBITDA ($1.4M Q4, $4.5M full year). 
  - Operating income 3-4% of revenue in 2025. 
- **Balance Sheet**: $69.4M cash, including $20M from Valor Equity. 

**【Q&A Key Takeaways】**
1. **Sales Drivers**: Enterprise accounts, OCD demand, elderly MDD utilization. 
2. **Protocol Timing**: Accelerated MDD data Q3 2025; AUD trial H2 2025. 
3. **Margin Outlook**: 75% gross margin maintained in 2025. 
4. **Partnerships**: Growing psychedelic therapy clinics adopting Deep TMS. 
5. **Regulatory Tailwinds**: PTSD reimbursement expansion in Israel; reduced MDD treatment failures threshold. 
6. **Organic Growth Focus**: No active M&A plans; investing in R&D and enterprise partnerships.

BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

- **Revenue Surge**: Q1 2024 revenue up 37% YoY to $9.1 million, with 57 systems shipped and 1,158 total installed base.
- **Profitability Milestones**: 75% gross margin, positive net income and EBITDA for third straight quarter.
- **Growth Drivers**: Katie’s Way Plus expands to 40 systems; international expansion in Korea, Taiwan, India.
- **Pipeline Progress**: Neurology CE Mark approvals, short protocol clinical trial, and addiction partnerships in development.
- **Cash Position**: $47.8 million cash, with plans to reinvest in sales, marketing, and R&D while maintaining profitability.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2024 revenue of $9.1 million, up 37% YoY, driven by 57 Deep TMS systems shipped (vs. 42 in Q1 2023). Total installed base reached 1,158 systems (+24% YoY). 
- **Profitability**: Gross margin improved to 75% (vs. 73% YoY), with $6.8 million gross profit. Positive net income ($100k) and EBITDA ($700k) for the third consecutive quarter.
- **Market Expansion**: Strong demand in U.S. and international markets (Korea, Taiwan, India). 18 new systems ordered by Katie’s Way Plus, expanding to 40 devices. Israel expansion supported by increased reimbursement rates.
- **Product Adoption**: 50% of installed base now includes OCD coils. New Deep TMS 360 clinical trial launched for accelerated protocols.
- **Leadership Updates**: Appointed Honny Groen as VP of International Sales and Dr. Musayev as CTO to drive global growth and R&D.

**【CFO Financial Commentary】**
- **Top Line Guidance**: Reaffirmed 2024 revenue guidance of $37-40 million (16-26% YoY growth). Q1 bookings on track with strong backlog.
- **Cost Efficiency**: Operating expenses down 21% YoY to $6.7 million. Sales & marketing expenses reduced 22% to $3.8 million.
- **Liquidity**: $47.8 million cash on hand (no debt), with third consecutive quarter of positive cash flow.

**【Q&A Key Highlights】**
- **Geographic Expansion**: Focus on Korea, Taiwan, India, and Europe. U.S. demand strong across all states.
- **Clinical Pipeline**: 
  - Neurology indications (Parkinson’s, epilepsy) gaining traction internationally with CE Mark.
  - Short protocol clinical trial with FDA to reduce treatment duration.
  - Addiction partnerships in development, with potential agreements by end-2024.
- **Customer Mix**: Growth from both new customers (mid-sized mental health networks) and existing accounts expanding capacity.
- **Capital Allocation**: Plans to reinvest cash into sales team expansion, marketing, and R&D while maintaining profitability.
- **Reimbursement Trends**: Insurance standards shifting to require failure of 1-2 medications before Deep TMS, up from 3-4 previously, driven by cost savings and efficacy data.

Actual					-0.075	-0.015	-0.02	-0.01	-0.055	-0.03	-0.025	-0.02	-0.03	-0.035	-0.075	-0.06	-0.035	-0.025	-0.005	0	0	0.01	0.01	0.02	0.01	0.025	0.02	0.035
Forecast					-0.0763	-0.0613	-0.0288	-0.025	-0.038	-0.033	-0.031	-0.0292	-0.0367	-0.035	-0.0317	-0.0625	-0.0539	-0.0418	-0.0224	-0.0065	-0.0083	-0.0013	0.005	0.0113	0.0113	0.0163	0.0233	0.0311
Surprise	0.00%	0.00%	0.00%	0.00%	+1.70%	+75.53%	+30.56%	+60.00%	-44.74%	+9.09%	+19.35%	+31.51%	+18.26%	0.00%	-136.59%	+4.00%	+35.06%	+40.19%	+77.68%	+100.00%	+100.00%	+869.23%	+100.00%	+76.99%	-11.50%	+53.37%	-14.16%	+12.54%

BWAY

BWAY fundamentals

BWAY Q4 2025 Earnings

Earnings Call

You can ask Aime

BWAY

BWAY fundamentals

BWAY Q4 2025 Earnings

Earnings Call

BWAY Earnings Call Summary for Q4/20258:30 AM on Mar 11, 2026

BWAY Earnings Call Summary for Q3/20258:30 AM on Nov 11, 2025

BWAY Earnings Call Summary for Q2/20258:00 AM on Aug 13, 2025

BWAY Earnings Call Summary for Q1/20258:30 AM on May 13, 2025

BWAY Earnings Call Summary for Q4/20248:30 AM on Mar 11, 2025

You can ask Aime